Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Purpose: Despite several prospective trials showing a clinical benefit of combining external beam radiotherapy (EBRT) with brachytherapy boost (BTB) for the treatment of intermediate- and high-risk prostate cancer (PCa) patients, none of these trials was designed to test for a survival difference. In this study, we aimed to collect a large multi-institutional database to determine whether BT boost was associated with a statistically significant improvement in survival and a reduction of distant metastases based on real-world data.
Material And Methods: We collected the data of patients treated for intermediate- or high-risk PCa with definitive EBRT or BTB, with or without androgen deprivation therapy (ADT), between January 2003 and December 2014 at two tertiary institutions. The statistical endpoints included overall survival (OS), freedom from distant metastases (FFDM), and metastases-free survival (MFS). The impact of treatment modality was assessed using Cox regression models and log-rank testing after one-to-one propensity score matching.
Results: A total of 1641 patients treated with EBRT (n = 1148) or high-dose-rate BTB (n = 493) were analyzed. The median survival and clinical follow-up were 117.8 (IQR 78-143.3) and 60.7 months, respectively. The radiotherapy modality (BTB) remained an independent prognostic factor for OS (HR 0.75; 95% CI 0.63-0.88; p < 0.001), FFDM (HR 0.54; 95% CI 0.4-0.73; p < 0.001), and MFS (HR 0.72; 95% CI 0.61-0.85; p < 0.001). After propensity score matching, the remaining 986 patients were well-balanced in terms of age, maximum PSA, ISUP grade group, and TNM T stage. OS (p < 0.001), FFDM (p = 0.001) and MFS (p < 0.001) were significantly higher in the BTB group.
Conclusions: There is a strong positive association between BTB and OS, FFDM, and MFS in PCa patients treated with definitive RT for intermediate- or high-risk PCa.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.radonc.2023.109632 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rapid Metastatic Growth of A Pancreatic Signet Ring Cell Carcinoma within 6 weeks of A Negative CT.
Eur J Case Rep Intern Med
August 2025
Division of Gastroenterology, Department of Medicine, Staten Island University Hospital, Northwell Health, Staten Island, USA.
Unlabelled: Pancreatic signet ring cell carcinoma (PSRCC) is a rare and aggressive subtype of pancreatic cancer with a dismal prognosis. We present the case of a 50-year-old male who, within six weeks, developed a pancreatic mass with liver metastases. Endoscopic ultrasound-guided biopsy confirmed PSRCC.
View Article and Find Full Text PDFUtilizing tumor deposit count as a stratification criterion in revising TNM staging system for patients with colorectal cancer: a nomogram review study.
Front Oncol
August 2025
Department of Surgery, Hebei Medical University, Shijiazhuang, Hebei, China.
Background: Tumor deposit (TD) is an independent risk factor associated with recurrence or metastasis for patients with colorectal cancer (CRC). The scenario in which both TD and lymph node metastasis (LNM) are positive is not clearly illustrated by the current TNM staging system. Simply treating one TD as one or two LNMs by a weighting factor is inappropriate.
View Article and Find Full Text PDFMutation-based, neoadjuvant treatment for advanced anaplastic thyroid carcinoma.
Front Endocrinol (Lausanne)
September 2025
Department of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Marburg, Germany.
Introduction: The prognosis of anaplastic thyroid carcinoma (ATC) remains poor. Mutation-based targeted therapies and immune checkpoint inhibitors (ICI) have gained increasing importance in the treatment of advanced tumor stages. This study aimed to investigate whether mutation-based neoadjuvant therapy can convert an initially unresectable tumor into a resectable state, optimizing local tumor control and prolonging overall survival.
View Article and Find Full Text PDFRare Metastases to Liver and Spleen form a Seldom Case of Facial Angiosarcoma Demonstrated on Staging FDG PET-CT.
Indian J Nucl Med
August 2025
Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
Angiosarcoma is a rare type of soft-tissue sarcoma, constituting only 1% out of all soft-tissue sarcomas pathologically originating from lymphatic or vascular endothelial cells. Angiosarcomas are reported to be very aggressive with a high incidence of metastases to different sites; therefore, it is very important to determine disease extension and detect local recurrence and/or distant metastases for appropriate management. We report a case of a 55-year-old Indian male who presented with soft-tissue thickening of the left cheek for which biopsy revealed angiosarcoma and was referred for fludeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) to assess the extent of disease highlighting the potential role of FDG PET/CT in rare malignancies like angiosarcomas.
View Article and Find Full Text PDFEvaluating the Oncologic and Safety Outcomes of High-Dose Palliative Radiation Treatment with 30 Grays in Five Fractions.
Cureus
August 2025
Division of Radiation Oncology and Developmental Radiotherapeutics, BC Cancer - Vancouver, Vancouver, CAN.
Introduction In select tumor sites, symptom palliation and local control can be improved through delivering higher biological equivalent doses (BED) of radiotherapy. However, not all patients are suitable candidates for stereotactic body radiation therapy (SBRT). The 30 Grays in five fractions (30/5) regimen is a conformal, hypofractionated regimen that offers a higher BED compared to conventional palliative radiotherapy.
View Article and Find Full Text PDF